{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T15:21:38Z","timestamp":1771600898864,"version":"3.50.1"},"reference-count":266,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.nefroe.2023.03.003","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T10:07:56Z","timestamp":1684231676000},"page":"1-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S1","title":["Recommendations of the Spanish Society of Nephrology for the management of mineral and bone metabolism disorders in patients with chronic kidney disease: 2021 (SEN-MM)"],"prefix":"10.1016","volume":"43","author":[{"given":"Jos\u00e9-Vicente","family":"Torregrosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Bover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Rodr\u00edguez Portillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Gonz\u00e1lez Parra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Dolores Arenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Caravaca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda-Luisa","family":"Gonz\u00e1lez Casaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Mart\u00edn-Malo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Francisco","family":"Navarro-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minerva","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cannata Andia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2023.03.003_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-6386(03)00905-3","article-title":"National Kidney Foundation: K\/DOQI Clinical Practice Guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0010","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Kidney Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0015","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD\u2013MBD)","volume":"76","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD\u2013MBD Work Group","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease\u2013Mineral and Bone Disorder (CKD-MBD)","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0025","series-title":"The Kidney","first-page":"2103","article-title":"Renal osteodystrophies","author":"Llach","year":"2000"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ndt\/11.supp3.22","article-title":"A d\u00e9ficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism","volume":"11","author":"Martinez","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0035","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.nefro.2018.06.008","article-title":"Utilidad de los par\u00e1metros urinarios en la enfermedad renal cr\u00f3nica avanzada","volume":"39","author":"Lorenzo","year":"2019","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0040","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1681\/ASN.2009080815","article-title":"Reduced hepatic synthesis of calcidiol in uremia","volume":"21","author":"Michaud","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41581-018-0078-3","article-title":"The Klotho proteins in health and disease","volume":"15","author":"Kuro","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0050","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1038\/ki.2011.26","article-title":"Phosphate and klotho","volume":"79","author":"Kuro","year":"2011","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0055","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1096\/fj.201700006R","article-title":"Differential regulation of renal Klotho and FGFR1 in normal and uremic rats","volume":"31","author":"Mu\u00f1oz-Casta\u00f1eda","year":"2017","journal-title":"FASEB J"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0060","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1038\/s41467-019-12399-9","article-title":"Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion","volume":"10","author":"Centeno","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0065","first-page":"s65","article-title":"Uremic toxins and vitamin D metabolism","volume":"62","author":"Hsu","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0070","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/jbmr.5650110714","article-title":"Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro","volume":"11","author":"Almaden","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0075","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1172\/JCI118701","article-title":"Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro","volume":"97","author":"Slatopolsky","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0080","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/oxfordjournals.ndt.a027665","article-title":"A direct effect in vitro of phosphate on PTH release from bovine parathyroid tissue slices but not from dispersed parathyroid cells","volume":"11","author":"Nielsen","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0085","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1681\/ASN.V9101845","article-title":"High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro","volume":"9","author":"Almaden","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0090","doi-asserted-by":"crossref","first-page":"e13662","DOI":"10.7554\/eLife.13662","article-title":"Structural mechanism of ligand activation in human calcium-sensing receptor","volume":"5","author":"Geng","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0095","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1093\/ndt\/gfn338","article-title":"Simultaneous changes in the calcium-sensing receptor and the vitamin D receptor under the influence of calcium and calcitriol","volume":"23","author":"Carrillo-Lopez","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0100","doi-asserted-by":"crossref","first-page":"F1390","DOI":"10.1152\/ajprenal.00262.2006","article-title":"The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands","volume":"292","author":"Rodriguez","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0105","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41598-018-19677-4","article-title":"Identification and quantification of plasma calciprotein particles with distinct physical properties in patients with chronic kidney disease","volume":"8","author":"Miura","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0110","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/sj.ki.5002646","article-title":"Metabolic acidosis inhibits soft tissue calcification in uremic rats","volume":"73","author":"Mendoza","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0115","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1111\/j.1523-1755.2004.09004.x","article-title":"Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD)","volume":"90","author":"Qunibi","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0120","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrneph.2014.49","article-title":"Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease","volume":"10","author":"Scialla","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0125","first-page":"28","article-title":"Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease","volume":"35","author":"Bover","year":"2015","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0130","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0135","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mce.2016.05.008","article-title":"Update on FGF23 and Klotho signaling","volume":"432","author":"Erben","year":"2016","journal-title":"Mol Cell Endocrinol"},{"issue":"Suppl 1","key":"10.1016\/j.nefroe.2023.03.003_bib0140","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s10157-016-1357-6","article-title":"The FGF23 and Klotho system beyond mineral metabolism","volume":"21","author":"Kuro","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0145","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO4, Ca x PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0150","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/01.ASN.0000113243.24155.2F","article-title":"Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes","volume":"15","author":"Stevens","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0155","series-title":"Clinical guide to the basics of bone and mineral metabolism in CKD","first-page":"77","article-title":"Morbidity and mortality associated with abnormalities in bone and mineral metabolism in CKD","author":"Block","year":"2006"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0160","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S2213-8587(14)70059-2","article-title":"Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders","volume":"2","author":"Vervloet","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0165","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1053\/j.ajkd.2005.04.006","article-title":"Mild hyperphosphatemia and mortality in hemodialysis patients","volume":"46","author":"Rodriguez-Benot","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0170","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S2213-8587(17)30310-8","article-title":"Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population","volume":"6","author":"Covic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0175","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0180","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1681\/ASN.2004040275","article-title":"Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS Waves 1, 3, and 4 study","volume":"16","author":"Slinin","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0185","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevel\u00e1mer and calcium-based phosphate binders on mortality in hemodialysis patients","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0190","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0195","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1053\/j.ajkd.2003.12.003","article-title":"Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy","volume":"43","author":"Martin","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0200","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1681\/01.asn.0000926800.06119.85","article-title":"Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology: mineral metabolism","volume":"17","author":"Jindal","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0205","first-page":"34","article-title":"Monitorizaci\u00f3n del paciente en hemodi\u00e1lisis","volume":"26","author":"Gonzalez-Parra","year":"2006","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0210","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.ki.5001606","article-title":"Inter-method variability in PTH measurement: implication for the care of CKD patients","volume":"70","author":"Souberbielle","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0215","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","article-title":"Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values","volume":"53","author":"Levey","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0220","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000492238","article-title":"Role of albumin assay on calcium levels and prescription of phosphate binders in chronic hemodialysis patients","volume":"140","author":"de Roij van Zuijdewijn","year":"2018","journal-title":"Nephron"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0225","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1681\/ASN.2007040449","article-title":"Pitfalls of measuring total blood calcium in patients with CKD","volume":"19","author":"Gauci","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0230","first-page":"573","article-title":"Plasma calcium in haemodialysis patients: total calcium or ionized calcium? Should we systematically provide a value of total corrected calcium on our protocols?","volume":"66","author":"Monfort","year":"2008","journal-title":"Ann Biol Clin (Paris)"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0235","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1440-1797.2009.01121.x","article-title":"Serum phosphate is an important determinant of corrected serum calcium in end-stage kidney disease","volume":"14","author":"Ferrari","year":"2009","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0240","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1053\/j.ajkd.2015.06.023","article-title":"Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis","volume":"67","author":"Sprague","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0245","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1053\/j.ajkd.2017.07.019","article-title":"KDOQI US Commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"70","author":"Isakova","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0250","first-page":"3","article-title":"Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.)","volume":"31","author":"Torregrosa","year":"2011","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0255","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/ki.1987.94","article-title":"Uremic cardiomyopathy: an inadequate left ventricular hypertrophy","volume":"31","author":"London","year":"1987","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0260","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/ndt\/gfv099","article-title":"COSMOS group. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study","volume":"30","author":"Fern\u00e1ndez-Mart\u00edn","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0265","first-page":"123","article-title":"Different biological functions in PTH molecules. What are we measuring?","volume":"28","author":"de la Piedra","year":"2008","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0270","first-page":"330","article-title":"A lower proportion of circulating active parathyroid hormone in peritoneal dialysis does not allow the pth inter-method adjustment proposed for haemodialysis","volume":"34","author":"Gonz\u00e1lez-Casaus","year":"2014","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0275","doi-asserted-by":"crossref","first-page":"524","DOI":"10.2215\/CJN.01730218","article-title":"Clear the fog around parathyroid hormone assays. What do iPTH assays really measure?","volume":"13","author":"Hocher","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0280","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000499187","article-title":"Rationale for raising current clinical practice guideline target for serum 25-hydroxyvitamin D in chronic kidney disease","volume":"49","author":"Strugnell","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0285","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000499160","article-title":"Aiming too low: reevaluation of target concentrations of serum 25-hydroxyvitamin D in secondary hyperparathyroidism","volume":"49","author":"Berg","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0290","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1093\/ndt\/gfy016","article-title":"Vitamin D status and mortality risk among patients on dialysis: a systematic review and meta-analysis of observational studies","volume":"33","author":"Zhang","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0295","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1809944","article-title":"Vitamin D supplements and prevention of cancer and cardiovascular disease","volume":"380","author":"Manson","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0300","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s00223-020-00781-5","article-title":"The non-invasive diagnosis of bone disorders in CKD","volume":"108","author":"Bover","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0305","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.kint.2017.07.021","article-title":"Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation","volume":"92","author":"Pimentel","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0310","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00223-018-0399-z","article-title":"Alkaline phosphatases in the complex chronic kidney disease-mineral and bone disorders","volume":"103","author":"Bover","year":"2018","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0315","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/ndt\/gfaa192","article-title":"European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D","volume":"36","author":"Evenepoel","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0320","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1681\/ASN.2008010014","article-title":"Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients","volume":"19","author":"Regidor","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0325","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.2215\/CJN.06091108","article-title":"Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients","volume":"4","author":"Shantouf","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0330","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nrneph.2017.60","article-title":"Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD","volume":"13","author":"Haarhaus","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0335","doi-asserted-by":"crossref","first-page":"e0159858","DOI":"10.1371\/journal.pone.0159858","article-title":"Alkalosis and dialytic clearance of phosphate increases phosphatase activity: a hidden consequence of hemodialysis","volume":"11","author":"Villa-Bellosta","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0340","doi-asserted-by":"crossref","first-page":"11089","DOI":"10.1038\/s41598-018-29432-4","article-title":"Hydrolysis of extracellular pyrophosphate increases in post-hemodialysis plasma","volume":"8","author":"Azpiazu","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0345","doi-asserted-by":"crossref","first-page":"e0183730","DOI":"10.1371\/journal.pone.0183730","article-title":"Impact of post-dialysis calcium level on ex vivo rat aortic wall calcification","volume":"12","author":"Azpiazu","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0350","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.nefro.2017.07.005","article-title":"Role of pyrophosphate in vascular calcification in chronic kidney disease","volume":"38","author":"Azpiazu","year":"2018","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0355","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/CIRCULATIONAHA.119.044195","article-title":"Slowing Progression of cardiovascular calcification with SNF472 in patients on hemodialysis: results of a randomized phase 2b study","volume":"141","author":"Raggi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0360","first-page":"486","article-title":"Increased serum phosphate concentrations in patients with advanced chronic kidney disease treated with diuretics","volume":"33","author":"Caravaca","year":"2013","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0365","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.nefro.2016.11.012","article-title":"C\u00f3mo estimar la eficacia de un captor del f\u00f3sforo","volume":"37","author":"Caravaca","year":"2017","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0370","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3390\/nu13020292","article-title":"Assessment of Inorganic Phosphate Intake by the Measurement of the Phosphate\/Urea Nitrogen Ratio in Urine","volume":"13","author":"Pend\u00f3n-Ruiz de Mier","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0375","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1681\/ASN.2014010104","article-title":"Proteinuria increases plasma phosphate by altering its tubular handling","volume":"26","author":"de Seigneux","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0380","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1681\/ASN.2017070772","article-title":"Longitudinal FGF23 trajectories and mortality in patients with CKD","volume":"29","author":"Isakova","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0385","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Guti\u00e9rrez","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0390","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3389\/fendo.2018.00189","article-title":"FGF23 actions on target tissues-with and without klotho","volume":"9","author":"Richter","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0395","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cca.2020.03.013","article-title":"FGF23 measurement in chronic kidney disease: what is it really reflecting?","volume":"505","author":"Vervloet","year":"2020","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0400","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.atherosclerosis.2020.04.017","article-title":"Calciprotein particles: a mineral biomarker in need of better measurement","volume":"303","author":"Smith","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0405","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1681\/ASN.2018030289","article-title":"The quest for better biomarkers of bone turnover in CKD","volume":"29","author":"Nickolas","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0410","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/ndt\/gfh217","article-title":"A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients","volume":"19","author":"Adragao","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0415","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0021-9150(97)00106-8","article-title":"New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study","volume":"132","author":"Kauppila","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0420","doi-asserted-by":"crossref","first-page":"654","DOI":"10.2215\/CJN.07450714","article-title":"Vascular calcification in patients with nondialysis CKD over 3 years","volume":"10","author":"G\u00f3rriz","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0425","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1525-139X.2007.00259.x","article-title":"Techniques and technologies to assess vascular calcification","volume":"20","author":"Bellasi","year":"2007","journal-title":"Semin Dial"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0430","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2369-14-22","article-title":"Fibroblast growth factor 23 is associated with carotid artery calcification in chronic kidney disease patients not undergoing dialysis: a cross-sectional study","volume":"14","author":"Nakayama","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0435","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1080\/14656566.2016.1182155","article-title":"Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification","volume":"17","author":"Bover","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0440","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1080\/14656566.2016.1182985","article-title":"Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification","volume":"17","author":"Bover","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0445","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/ndt\/gfv020a","article-title":"Opponent\u2019s comments","volume":"30","author":"Zoccali","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0450","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.nefro.2017.12.006","article-title":"Osteoporosis, bone mineral density and CKD-MBD complex (I): diagnostic considerations","volume":"38","author":"Bover","year":"2018","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0455","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.2215\/CJN.09500916","article-title":"Fractures in patients with CKD: time for action","volume":"11","author":"Moe","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0460","doi-asserted-by":"crossref","first-page":"962","DOI":"10.2215\/CJN.11031017","article-title":"Management of Osteoporosis in CKD","volume":"13","author":"Khairallah","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0465","doi-asserted-by":"crossref","first-page":"646","DOI":"10.2215\/CJN.06040614","article-title":"Comparison of fracture risk prediction among individuals with reduced and normalkidney function","volume":"10","author":"Naylor","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0470","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00198-013-2524-1","article-title":"The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease","volume":"25","author":"Jamal","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0475","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S8756-3282(96)00246-3","article-title":"Retrospective study on the usefulness of radius and lumbar bone density in the separation of hemodialysis patients with fractures from those without fractures","volume":"19","author":"Yamaguchi","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0480","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1093\/ndt\/gfg403","article-title":"Bone mineral density, biochemical markers and skeletal fractures in hemodialysis patients","volume":"18","author":"Ure\u00f1a","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0485","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.2215\/CJN.01470209","article-title":"Arteriovenous fistula affects bone mineral density measurements in end-stage renal failure patients","volume":"4","author":"Muxi","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0490","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/ndt\/gfw468","article-title":"Bone biopsy practice patterns across Europe: the European renal osteodystrophy initiative\u2014a position paper","volume":"32","author":"Evenepoel","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 3","key":"10.1016\/j.nefroe.2023.03.003_bib0495","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2215\/CJN.02430508","article-title":"The role of bone biopsy in patients with chronic renal failure","volume":"3","author":"Miller","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0500","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5527\/wjn.v6.i3.100","article-title":"Role of different imaging modalities of vascular calcification in predicting outcomes in chronic kidney disease","volume":"6","author":"Disthabanchong","year":"2017","journal-title":"World J Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0505","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0510","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1148\/radiology.208.3.9722864","article-title":"Coronary artery disease: improved reproducibility of calcium scoring with an electron-beam CT volumetric method","volume":"208","author":"Callister","year":"1998","journal-title":"Radiology"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0515","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.kint.2016.06.041","article-title":"Parathyroid hormone metabolism and signaling in health and chronic kidney disease","volume":"90","author":"Evenepoel","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0520","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.nefro.2020.12.019","article-title":"Hiporrespuesta o resistencia a la acci\u00f3n de la hormona paratiroidea en la enfermedad renal cr\u00f3nica","volume":"41","author":"Bover","year":"2021","journal-title":"Nefrolog\u00eda"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0525","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/ki.1986.252","article-title":"The absorption of dietary phosphorus and calcium in hemodialysis patients","volume":"30","author":"Ramirez","year":"1986","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0530","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3945\/ajcn.2008.26665","article-title":"Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?","volume":"88","author":"Shinaberger","year":"2008","journal-title":"Am J Clin Nutr"},{"issue":"3 Suppl 1","key":"10.1016\/j.nefroe.2023.03.003_bib0535","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","article-title":"KDOQI clinical practice guideline for nutrition in CKD: 2020 update","volume":"76","author":"Ikizler","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0540","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2215\/CJN.05040610","article-title":"Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease","volume":"6","author":"Moe","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0545","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.ekir.2020.08.008","article-title":"Pilot randomized controlled trial of a standard versus a modified low-phosphorus diet in hemodialysis patients","volume":"5","author":"Byrne","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0550","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1210\/jc.2010-2704","article-title":"The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know","volume":"96","author":"Ross","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0555","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0560","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ndt\/gfw082","article-title":"Pro: should we correct vitamin D deficiency\/insufficiency in chronic kidney disease patients with inactive forms of vitamin D or just treat them with active vitamin D forms?","volume":"31","author":"Goldsmith","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0565","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/ndt\/gfw080","article-title":"Con: nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease","volume":"31","author":"Agarwal","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0570","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/ndt\/gfw081","article-title":"Moderator\u2019s view: vitamin D deficiency treatment in advanced chronic kidney disease: a close look at the emperor\u2019s clothes","volume":"31","author":"Zoccali","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0575","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/ki.2011.490","article-title":"Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets","volume":"81","author":"Spiegel","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0580","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/ki.2012.403","article-title":"Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease","volume":"83","author":"Hill","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0585","doi-asserted-by":"crossref","first-page":"e0133938","DOI":"10.1371\/journal.pone.0133938","article-title":"New conclusions regarding comparison of sevelamer and calcium-based phosphate binders in coronary-artery calcification for dialysis patients: a meta-analysis of randomized controlled trials","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0590","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2215\/CJN.01650211","article-title":"Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients","volume":"6","author":"Navarro-Gonz\u00e1lez","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0595","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.nefro.2015.05.022","article-title":"Use of sevelamer in chronic kidney disease: beyond phosphorus control","volume":"35","author":"Rodr\u00edguez-Osorio","year":"2015","journal-title":"Nefrologia"},{"issue":"10","key":"10.1016\/j.nefroe.2023.03.003_bib0600","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.2215\/CJN.02420409","article-title":"Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study","volume":"4","author":"Navarro-Gonz\u00e1lez","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0605","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/sj.ki.5002059","article-title":"Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients","volume":"71","author":"Block","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0610","doi-asserted-by":"crossref","first-page":"e0156891","DOI":"10.1371\/journal.pone.0156891","article-title":"Comparative effectiveness of phosphate binders in patients with chronic kidney disease: a systematic review and network meta-analysis","volume":"11","author":"Sekercioglu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0615","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2215\/CJN.06800615","article-title":"Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials","volume":"11","author":"Patel","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0620","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1053\/j.ajkd.2016.05.015","article-title":"Phosphate-binding agents in adults with CKD: a network meta-analysis of randomized trials","volume":"68","author":"Palmer","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0625","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.2165\/11202610-000000000-00000","article-title":"Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease","volume":"69","author":"Curran","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0630","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1185\/03007990903399398","article-title":"Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy","volume":"25","author":"Wilson","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0635","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1159\/000488700","article-title":"Effect of lanthanum carbonate on all-cause mortality in patients receiving maintenance hemodialysis: a meta-analysis of randomized controlled trials","volume":"43","author":"Wang","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0640","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1093\/ndt\/gfq292","article-title":"Evaluation of calcium acetate\/magnesium carbonate as a phosphate binder compared with sevel\u00e1mer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability","volume":"25","author":"de Francisco","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0645","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1542-4758.2009.00364.x","article-title":"Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study","volume":"13","author":"Spiegel","year":"2009","journal-title":"Hemodial Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0650","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s11255-014-0751-9","article-title":"Magnesium retards the progress of the arterial calcifications in hemodialysis patients: a pilot study","volume":"46","author":"Tzanakis","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0655","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1684\/mrh.2016.0412","article-title":"Magnesium-based interventions for normal kidney function and chronic kidney disease","volume":"29","author":"Massy","year":"2016","journal-title":"Magnes Res"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0660","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3390\/nu9020112","article-title":"Effects of magnesium on the phosphate toxicity in chronic kidney disease: time for intervention studies","volume":"9","author":"Sakaguchi","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0665","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1080\/14656566.2018.1491548","article-title":"Sucroferric oxyhydroxide for the treatment of hyperphosphatemia","volume":"19","author":"Sprague","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0670","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.nefro.2018.05.003","article-title":"Pharmacological interactions of phosphate binders. Interacciones farmacol\u00f3gicas de los captores del f\u00f3sforo","volume":"38","author":"Bover","year":"2018","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0675","first-page":"522","article-title":"Captores del f\u00f3sforo: preferencias de los pacientes en hemodi\u00e1lisis y su repercusi\u00f3n sobre el cumplimiento del tratamiento y el control del f\u00f3sforo","volume":"30","author":"Arenas","year":"2010","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0680","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/ki.2013.185","article-title":"Use of phosphate-binding agents is associated with a lower risk of mortality","volume":"84","author":"Cannata-And\u00eda","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0685","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1681\/ASN.2008060609","article-title":"Phosphorus binders and survival on hemodialysis","volume":"20","author":"Isakova","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0690","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","article-title":"Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis","volume":"382","author":"Jamal","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0695","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1681\/ASN.2012030223","article-title":"Effects of phosphate binders in moderate CKD","volume":"23","author":"Block","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0700","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1681\/ASN.2020040411","article-title":"Randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMPROVE-CKD)","volume":"31","author":"Toussaint","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0705","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1681\/ASN.2018101058","article-title":"Effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor-23 in CKD: the COMBINE Trial","volume":"30","author":"Ix","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0710","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/ndt\/6.9.605","article-title":"Insights into the complex aluminium and iron relationship","volume":"6","author":"Cannata","year":"1991","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0715","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.beem.2011.05.005","article-title":"Vitamin D in chronic kidney disease","volume":"25","author":"Dusso","year":"2011","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0720","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2007111164","article-title":"Association of oral calcitriol with improved survival in nondialyzed CKD","volume":"19","author":"Shoben","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0725","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2007.110","article-title":"Association of activated vitamin D treatment and mortality in chronic kidney disease","volume":"25;168","author":"Kovesdy","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0730","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10157-009-0233-z","article-title":"Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events","volume":"14","author":"Sugiura","year":"2010","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0735","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.070305","article-title":"Differential effects of vitamin D analogs on vascular calcification","volume":"22","author":"Cardus","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0740","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/sj.ki.5002406","article-title":"Differential effects of vitamin D receptor activators on vascular calcification in uremic rats","volume":"72","author":"Mizobuchi","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0745","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00684.2011","article-title":"In vascular smooth muscle cells paricalcitol prevents phosphate-induced Wnt\/\u03b2-catenin activation","volume":"303","author":"Mart\u00ednez-Moreno","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0750","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","article-title":"Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial","volume":"376","author":"de Zeeuw","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0755","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1172\/JCI0215219","article-title":"1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system","volume":"110","author":"Li","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0760","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1681\/ASN.2004070573","article-title":"Activated injectable vitamin D and hemodialysis survival: a historical cohort study","volume":"16","author":"Teng","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0765","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/ejcn.2017.59","article-title":"Effects of vitamin D or its analogues on the mortality of patients with chronic kidney disease: an updated systematic review and meta-analysis","volume":"71","author":"Lu","year":"2017","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0770","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy","volume":"349","author":"Teng","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0775","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nefro.2017.05.012","article-title":"Changes in renal function after discontinuation of vitamin D analogues in advanced chronic kidney disease","volume":"38","author":"Caravaca","year":"2018","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0780","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2012.120","article-title":"Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial","volume":"307","author":"Thadhani","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0785","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1681\/ASN.2013010103","article-title":"Effect of paricalcitol on left ventricular mass and function in CKD\u2014the OPERA trial","volume":"25","author":"Wang","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0790","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1111\/j.1523-1755.2005.00330.x","article-title":"Progression of secondary hyperparathyroidism involves deregulation of genes related to DNA and RNA stability","volume":"67","author":"Santamaria","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0795","first-page":"469","article-title":"Genetic and molecular disorders in severe secondary hiperparathyroidism: lessons from RNA and microarrays studies","volume":"18","author":"Santamar\u00eda","year":"2005","journal-title":"J Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0800","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/ndt\/gfaa195","article-title":"The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation","volume":"36","author":"Tabibzadeh","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0805","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.113.204834","article-title":"Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients","volume":"346","author":"Walter","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0810","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0815","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1517\/14656566.6.3.441","article-title":"Cinacalcet HCL: a novel therapeutic for hyperparathyroidism","volume":"6","author":"De Francisco","year":"2005","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0820","first-page":"280","article-title":"Cinacalcet HCl (Sensipar\u2122) for the Management of Secondary Hyperparathyroidism (HPT) in patients receiving Peritoneal Dialysis (PD)","volume":"15","author":"MIittman","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0825","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2215\/CJN.00870805","article-title":"Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate","volume":"1","author":"Chertow","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0830","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000319882","article-title":"Cinacalcet Treatment for secondary hyperparathyroidism in dialysis patients: an observational study in routine clinical practice","volume":"118","author":"Bover","year":"2010","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0835","doi-asserted-by":"crossref","first-page":"F1376","DOI":"10.1152\/ajprenal.90737.2008","article-title":"The calcimimetic AMG 641 accelerates regression of extraosseous calcification in uremic rats","volume":"296","author":"Lopez","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0840","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/ndt\/gfs356","article-title":"Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study","volume":"28","author":"Ure\u00f1a-Torres","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0845","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism","volume":"68","author":"Cunningham","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0850","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1681\/ASN.2014040414","article-title":"Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial","volume":"26","author":"Moe","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0855","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2215\/CJN.07730814","article-title":"The effects of cinacalcet in older and younger patients on hemodialysis: the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial","volume":"10","author":"Parfrey","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0860","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2215\/CJN.01760215","article-title":"Clinical and practical use of calcimimetics in dialysis patients with secondary hyperparathyroidism","volume":"11","author":"Bover","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0865","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/1744-9987.12292","article-title":"Two years of cinacalcet hydrochloride treatment decreased parathyroid gland volume and serum parathyroid hormone level in hemodialysis patients with advanced secondary hyperparathyroidism","volume":"19","author":"Yamada","year":"2015","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0870","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0875","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/ckj\/sfaa005","article-title":"Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics","volume":"14","author":"Arenas","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0880","first-page":"158","article-title":"Usefulness of imaging techniques in secondary hyperparathyroidism","volume":"30","author":"Torregrosa","year":"2010","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0885","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2215\/CJN.03520414","article-title":"Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis","volume":"10","author":"Ishani","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0890","doi-asserted-by":"crossref","first-page":"952","DOI":"10.2215\/CJN.10390917","article-title":"Parathyroidectomy in the management of secondary hyperparathyroidism","volume":"13","author":"Lau","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0895","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/MNH.0000000000000327","article-title":"Hungry bone syndrome","volume":"26","author":"Jain","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0900","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1530\/EJE-12-0528","article-title":"Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature","volume":"168","author":"Witteveen","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0905","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2215\/CJN.12871211","article-title":"Bone mineral density and fracture risk in older individuals with CKD","volume":"7","author":"Yenchek","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0910","first-page":"288","article-title":"Use of bisphosphonates in chronic kidney disease","volume":"30","author":"Torregrosa","year":"2010","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0915","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0920","first-page":"7384763","article-title":"Denosumab-induced severe hypocalcaemia in Chronic Kidney Disease","volume":"2018","author":"Jalleh","year":"2018","journal-title":"Case Rep Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0925","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0930","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/jbmr.3722","article-title":"Relationship between bone mineral density T-score and nonvertebral fracture risk over 10 years of denosumab treatment","volume":"34","author":"Ferrari","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0935","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0940","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research [published correction appears in J Bone Miner Res 2016 Oct;31(10 ):1910]","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0945","unstructured":"Anexo 1. Ficha T\u00e9cnica Europea de FORSTEO\u00ae Teriparatida. [Accessed April 2021]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/forsteo-epar-product-information_es.pdf."},{"key":"10.1016\/j.nefroe.2023.03.003_bib0950","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/ki.1997.395","article-title":"Effect of dietary protein restriction on nutritional status in the Modification of Diet in Renal Disease Study","volume":"52","author":"Kopple","year":"1997","journal-title":"Kidney Int"},{"issue":"Suppl 3","key":"10.1016\/j.nefroe.2023.03.003_bib0955","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/ndt\/13.suppl_3.65","article-title":"Is it possible to control hyperphosphatemia with diet, without inducing protein malnutrition?","volume":"13","author":"Rufino","year":"1998","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 2","key":"10.1016\/j.nefroe.2023.03.003_bib0960","first-page":"57","article-title":"Role of diet in the management of osteodystrophy during progressive renal insufficiency","volume":"23","author":"Martinez","year":"2003","journal-title":"Nefrologia"},{"issue":"Suppl 85","key":"10.1016\/j.nefroe.2023.03.003_bib0965","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1046\/j.1523-1755.63.s85.11.x","article-title":"Vitamin D status and secondary hyperparathyroidism: the importance of 25-hydroxy vitamin D cut-off levels","volume":"63","author":"G\u00f3mez-Alonso","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0970","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3945\/ajcn.111.031427","article-title":"Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults","volume":"95","author":"Cashman","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0975","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4321\/S1889-836X2018000200005","article-title":"Calcifediol mensual frente a calcifediol quincenal en el tratamiento de pacientes osteopor\u00f3ticos. Estudio en la vida real","volume":"10","author":"Olmos","year":"2018","journal-title":"Rev Osteoporos Metab Miner"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0980","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000450766","article-title":"Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease","volume":"44","author":"Sprague","year":"2016","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0985","doi-asserted-by":"crossref","first-page":"c268","DOI":"10.1159\/000276579","article-title":"Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease","volume":"114","author":"Reichel","year":"2010","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0990","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.nefro.2018.10.009","article-title":"Osteoporosis, bone mineral density and CKD-MBD (II): therapeutic implications","volume":"39","author":"Bover","year":"2019","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2023.03.003_bib0995","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function","volume":"26","author":"Jamal","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1000","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/ndt\/gfaa054","article-title":"Impact of longer term phosphorus control on cardiovascular mortality in hemodialysis patients using an area under the curve approach: results from the DOPPS","volume":"35","author":"Barreto-Lopes","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1005","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/ndt\/gfy273","article-title":"Detecting high-risk chronic kidney disease-mineral bone disorder phenotypes among patients on dialysis: a historical cohort study","volume":"34","author":"Neri","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2215\/CJN.09360620","article-title":"Effect of phosphate-specific diet therapy on phosphate levels in adults undergoing maintenance hemodialysis: a systematic review and meta-analysis","volume":"16","author":"St-Jules","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/IJNRD.S165919","article-title":"Nocturnal hemodialysis: improved quality of life and patient outcomes","volume":"12","author":"Koh","year":"2019","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1020","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1111\/j.1523-1755.2005.09504.x","article-title":"The role of daily dialysis in the control of hyperphosphatemia","author":"Achinger","year":"2005","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1025","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/IJNRD.S35632","article-title":"Phosphate control in dialysis","volume":"6","author":"Cupisti","year":"2013","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1030","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1681\/ASN.2020050598","article-title":"Optimal phosphate control related to coronary artery calcification in dialysis patients","volume":"32","author":"Isaka","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1035","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1001\/jama.2021.4807","article-title":"LANDMARK Study Group","volume":"325","author":"Ogata","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1040","doi-asserted-by":"crossref","first-page":"e0201537","DOI":"10.1371\/journal.pone.0201537","article-title":"Phosphate control in reducing FGF23 levels in hemodialysis patients","volume":"13","author":"Rodelo-Haad","year":"2018","journal-title":"PLoS One"},{"issue":"3\u20134","key":"10.1016\/j.nefroe.2023.03.003_bib1045","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000366126","article-title":"Individualization of dialysate calcium concentration according to baseline pre-dialysis serum calcium","volume":"38","author":"Gonzalez-Parra","year":"2014","journal-title":"Blood Purif"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1050","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.nefro.2017.09.011","article-title":"Bone and mineral metabolism at 55 haemodialysis centres in Lima. Influencia de la sobrecarga de calcio sobre el metabolismo \u00f3seo y mineral en 55 centros de hemodi\u00e1lisis de Lima","volume":"38","author":"M\u00e9ndez-Chac\u00f3n","year":"2018","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1055","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/ndt\/gfh214","article-title":"Multicentre Study Group Collaborators. Low vs standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study","volume":"19","author":"S\u00e1nchez","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1060","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/ndt\/gfq219","article-title":"Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population","volume":"26","author":"Floege","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1065","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1093\/ndt\/gfq304","article-title":"Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study","volume":"26","author":"Naves-D\u00edaz","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1070","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2215\/CJN.12941213","article-title":"Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPSstudy","volume":"10","author":"Tentori","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1075","doi-asserted-by":"crossref","first-page":"e0146801","DOI":"10.1371\/journal.pone.0146801","article-title":"A new data analysis system to quantify associations between biochemical parameters of chronic kidney disease-mineral bone disease","volume":"11","author":"Rodriguez","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1080","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/sj.ki.5002257","article-title":"Adynamic bone disease and malnutrition-inflammation-cachexia syndrome","volume":"71","author":"Heaf","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1085","doi-asserted-by":"crossref","first-page":"e001363","DOI":"10.1161\/JAHA.114.001363","volume":"3","author":"Wheeler","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1090","doi-asserted-by":"crossref","first-page":"800","DOI":"10.2215\/CJN.10221014","article-title":"The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: the EVOLVE trial","volume":"10","author":"Floege","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1095","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ndt\/gfv050","volume":"30","author":"Goldsmith","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1100","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/ndt\/gfn502","article-title":"25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients","volume":"24","author":"Matias","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1105","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2215\/CJN.06510909","article-title":"Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters","volume":"5","author":"Matias","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1110","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/ndt\/gfw454","article-title":"Vitamin D treatment attenuates cardiac FGF23\/FGFR4 signaling and hypertrophy in uremic rats","volume":"32","author":"Leifheit-Nestler","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1115","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/ndt\/gfx060","article-title":"Regulation of miR-29b and miR-30c by vitamin D receptor activators contributes to attenuate uraemia-induced cardiac fibrosis","volume":"32","author":"Panizo","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1120","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/ndt\/gfs108","article-title":"VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH \u2264 150 pg\/mL: results of the Italian FARO Survey","volume":"27","author":"Cozzolino","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1125","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/j.jrn.2006.07.006","article-title":"Impact of kidney bone disease and its management on survival of patients on dialysis","volume":"17","author":"Lee","year":"2007","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1130","doi-asserted-by":"crossref","first-page":"F605","DOI":"10.1152\/ajprenal.90272.2008","article-title":"Direct upregulation of parathyroid calcium-sensing receptor and vitamin D receptor by calcimimetics in uremic rats","volume":"296","author":"Mendoza","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1135","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/sj.ki.5002675","article-title":"The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats","volume":"73","author":"Lopez","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1140","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1093\/ndt\/gfs018","article-title":"Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study","volume":"27","author":"Ketteler","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1145","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5500\/wjt.v5.i4.231","article-title":"Mineral and bone disorder after kidney transplantation","volume":"5","author":"Taweesedt","year":"2015","journal-title":"World J Transplant"},{"issue":"Suppl 3","key":"10.1016\/j.nefroe.2023.03.003_bib1150","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/ndt\/13.suppl_3.94","article-title":"Parathyroid function in long-term renal transplant patients: importance of pre-transplant PTH concentrations","volume":"13","author":"Torres","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1155","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.2215\/CJN.11371015","article-title":"Bone disease after kidney transplantation","volume":"11","author":"Bouquegneau","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1160","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1399-0012.2007.00690.x","article-title":"Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure","volume":"21","author":"Egbuna","year":"2007","journal-title":"Clin Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1165","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1600-6143.2007.01753.x","article-title":"Tertiary \u2018hyperphosphatonismaccentuates\u2019 hypophosphatemia and suppresses Calcitriol levels in renal transplant recipients","volume":"7","author":"Evenepoel","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1170","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1111\/j.1600-6143.2005.00938.x","article-title":"Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications","volume":"5","author":"Gwinner","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1175","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/SLA.0b013e3181728a2d","article-title":"Surgical treatment of persistent hyperparathyroidism after renal transplantation","volume":"248","author":"Triponez","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1180","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1681\/ASN.2015060622","article-title":"A Randomized study comparing parathyroidectomy with cinacalcet for treating hypercalcemia in kidney allograft recipients with hyperparathyroidism","volume":"27","author":"Cruzado","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1185","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/ndt\/gfl560","article-title":"Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients","volume":"22","author":"Serra","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1190","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40265-019-01074-4","article-title":"Management of post-transplant hyperparathyroidism and bone disease","volume":"79","author":"Delos Santos","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1195","doi-asserted-by":"crossref","first-page":"292654","DOI":"10.1155\/2015\/292654","article-title":"Long-term clinical practice experience with cinacalcet for treatment of hypercalcemic hyperparathyroidism after kidney transplantation","volume":"2015","author":"Thiem","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1200","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/TP.0b013e31817c13e1","article-title":"Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism","volume":"86","author":"Bergua","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1205","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1681\/ASN.V132551","article-title":"Calcium metabolism and skeletal problems after transplantatuion","volume":"13","author":"Torres","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1210","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1681\/ASN.2006050427","article-title":"Pathogenesis and prevention of bone loss in patients who have kidney disease and receive long-term immunosuppression","volume":"18","author":"Cunningham","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefroe.2023.03.003_bib1215","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00198-003-1532-y","article-title":"Long-term fracture risk following renal transplantation: a population-based study","volume":"15","author":"Vautour","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1220","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1097\/TP.0b013e3181a6bbda","article-title":"Risk of fractures after renal transplantation in the United States","volume":"87","author":"Nikkel","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1225","first-page":"CD005015","article-title":"Interventions for preventing bone disease in kidney transplant recipients","volume":"10","author":"Palmer","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1230","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1523-1755.2004.00432.x","article-title":"Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation","volume":"65","author":"Torres","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1235","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1097\/01.ASN.0000016082.70875.36","article-title":"Treatment with vitamin D y calcium reduces bone loss after renal transplantation: a randomized study","volume":"13","author":"De Sevaux","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1240","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1097\/01.ASN.0000093255.56474.B4","article-title":"Preventing bone loss in renal transplant recipients with vitamin D","volume":"14","author":"El-Agroudy","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1245","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/01.TP.0000137937.44703.42","article-title":"Calcium and calcitriol prophylaxis attenuates postransplant bone loss","volume":"78","author":"Josephson","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1250","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1159\/000446863","article-title":"Vitamin D in kidney transplant recipients: mechanisms and therapy","volume":"43","author":"Cianciolo","year":"2016","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1255","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1432-2277.2007.00501.x","article-title":"Weekly risedronate in kidney transplant patients with osteopenia","volume":"20","author":"Torregrosa","year":"2007","journal-title":"Transpl Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1260","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2215\/CJN.02550508","article-title":"Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue","volume":"4","author":"Toussaint","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1265","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1097\/01.ASN.0000087092.53894.80","article-title":"Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate","volume":"14","author":"Coco","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1270","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1681\/ASN.V1271530","article-title":"Effect of ibandronate on bone loss and renal function after kidney transplantation","volume":"12","author":"Grotz","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1275","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0041-1345(03)00479-2","article-title":"Alendronate for treatment of renal transplant patients with osteoporosis","volume":"35","author":"Torregrosa","year":"2003","journal-title":"Transp Proc"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1280","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1097\/TP.0b013e3181dc13d0","article-title":"Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients","volume":"89","author":"Torregrosa","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1285","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00198-010-1197-2","article-title":"Efficacy of low doses of pamidronate in osteopenic patients administered in the early post-renal transplant","volume":"22","author":"Torregrosa","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1290","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s00198-015-3465-7","article-title":"Bisphosphonates for prevention of osteopenia in kidney-transplant recipients: a systematic review of randomized controlled trials","volume":"27","author":"Wang","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1295","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/ctr.12792","article-title":"Outcomes of bisphosphonate therapy in kidney transplant recipients: a systematic review and meta-analysis","volume":"30","author":"Toth-Manikowski","year":"2016","journal-title":"Clin Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1300","doi-asserted-by":"crossref","first-page":"370","DOI":"10.5500\/wjt.v6.i2.370","article-title":"Risk factors for fracture in adult kidney transplant recipients","volume":"6","author":"Naylor","year":"2016","journal-title":"World J Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1305","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/01.TP.0000438200.84154.1a","article-title":"FRAX predicts fracture risk in kidney transplant recipients","volume":"97","author":"Naylor","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1310","doi-asserted-by":"crossref","first-page":"644","DOI":"10.2215\/CJN.09850916","article-title":"Spine trabecular bone score as an indicator of bone microarchitecture at the peripheral skeleton in kidney transplant recipients","volume":"12","author":"Luckman","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1315","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fendo.2018.00162","article-title":"Osteoporosis therapy with denosumab in organ transplant recipients","volume":"9","author":"Brunova","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1320","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1111\/ajt.13692","article-title":"Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial","volume":"16","author":"Bonani","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1325","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1097\/TP.0000000000001547","article-title":"Infections in de novo kidney transplant recipients treated with the RANKL inhibitor denosumab","volume":"101","author":"Bonani","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.nefroe.2023.03.003_bib1330","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00198-015-3377-6","article-title":"Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study","volume":"27","author":"Sumida","year":"2016","journal-title":"Osteoporos Int"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251423000573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251423000573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:50:43Z","timestamp":1761853843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251423000573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":266,"alternative-id":["S2013251423000573"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2023.03.003","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations of the Spanish Society of Nephrology for the management of mineral and bone metabolism disorders in patients with chronic kidney disease: 2021 (SEN-MM)","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2023.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2022.03.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}